Compare AGEN & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | SUNS |
|---|---|---|
| Founded | 1994 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 126.3M |
| IPO Year | 1999 | N/A |
| Metric | AGEN | SUNS |
|---|---|---|
| Price | $3.38 | $8.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.50 | $8.75 |
| AVG Volume (30 Days) | ★ 486.5K | 91.1K |
| Earning Date | 03-16-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 14.87% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $61.42 | $91.00 |
| Revenue Next Year | N/A | $20.79 |
| P/E Ratio | $8.89 | ★ $8.84 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $7.80 |
| 52 Week High | $7.34 | $11.78 |
| Indicator | AGEN | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 28.53 |
| Support Level | $2.91 | N/A |
| Resistance Level | $4.72 | $9.69 |
| Average True Range (ATR) | 0.27 | 0.27 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 38.97 | 4.58 |
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.